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OBJECTIVES The purpose of this study was to determine whether identification of contractile reserve with
dobutamine would predict recovery of myocardial function during follow-up in patients with
recent onset idiopathic dilated cardiomyopathy (IDC).
BACKGROUND The prognosis of patients presenting with new onset IDC is variable and difficult to predict.
METHODS Twenty-two patients (17 men, 5 women, 46 6 14 years) with recently diagnosed IDC (4 6
3 months) underwent dobutamine echocardiography. Left ventricular ejection fraction
(LVEF) and LV sphericity before and at peak dobutamine infusion (30 6 11 mg/kg/min)
were determined. A follow-up echocardiographic assessment was done at 6 6 4 months.
RESULTS The LVEF on dobutamine was directly related to baseline LV mass expressed as g/ml
(Pearson r 5 0.65, p 5 0.0003). Baseline variables that were significantly predictive of
follow-up LVEF were deceleration time (r 5 0.69, p 5 0.0006), wall motion score index
(WMSI) (r 5 20.63, p 5 0.002), LV mass (r 5 0.56, p 5 0.008) and LVEF on dobutamine
(r 5 0.84, p 5 0.0001). When either deceleration time or WMSI or LV mass was entered
into a regression equation to predict follow-up LVEF, the LVEF on dobutamine added
significantly to predictive power. However, if LVEF on dobutamine was entered first, none
of the other three variables added significantly to prediction. Baseline LV sphericity at end
diastole (ED) (r 5 0.13, p 5 0.6) did not correlate with follow-up LV sphericity in ED,
whereas LV sphericity in ED on dobutamine (ED [r 5 0.70, p 5 0.0004]) correlated with
LV sphericity in ED on follow up.
CONCLUSIONS This study demonstrates that dobutamine-induced improvement in baseline LVEF and LV
sphericity identifies patients with IDC who exhibit substantial improvement in LV function
and geometry over time. (J Am Coll Cardiol 1999;34:1537–44) © 1999 by the American
College of Cardiology
The natural history of recent onset idiopathic dilated
cardiomyopathy (IDC) is variable and difficult to predict.
The one-year mortality of these patients is as much as 25%
and five-year mortality ranges from 20% to 50% (1–2).
Conversely, a significant proportion of these patients im-
prove spontaneously over time (3–6). This high mortality
rate as well as the possibility of late spontaneous improve-
ment in cardiac function creates a management dilemma.
Idiopathic dilated cardiomyopathy accounts for 40% of
patients referred for heart transplantation, which improves
survival rates (7); however, this is a limited treatment option
(8).
As a consequence, the ability to identify patients with
IDC likely to recover myocardial function would be of
value. A restrictive diastolic left ventricle (LV) filling pattern
is associated with a poor prognosis in IDC (9,10). However,
symptoms, poor functional status (11), increased LV di-
mension (12), increased filling pressures (4,13), LV systolic
function (14), LV geometry (15), a combination of systolic
variables (16) and endomyocardial biopsy findings (17) do
not differentiate patients who need cardiac transplantation
from those who respond to medical therapy. The presence
of antimyocin antibodies at diagnosis of IDC is associated
with milder symptoms and greater functional capacity at one
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year (18); however, the value of these variables for predicting
the outcome of patients with recent onset IDC is not
established.
Changes in the adrenergic system are prognostic markers
of cardiac function (19). A rise in circulating catecholamines
is accompanied by decreased beta receptor density and
downregulation of the beta receptors (20) and is associated
with a poor response to beta-adrenergic blocking agents
(21) as well as a poor prognosis. A significant improvement
in LV function, shape (22,23) and prognosis (24) occurs in
response to beta blockade therapy in patients with IDC,
presumably from beta-receptor upregulation. Moreover, LV
hypertrophy (25) and increased myofibrillar to cell volume
ratio at myocardial biopsy are associated with a better
outcome in IDC (26). The myocardial contractile response
to exogenous catecholamine administration has prognostic
value in those with (27,28), or destined to develop (29),
chronic dilated cardiomyopathy. When combined, these
data suggest that LV hypertrophy and myofibril beta-
receptors may be critical to the maintenance of both
myocardial contractility and LV shape and that they confer
a prognostic benefit.
We hypothesized that, in patients with acute IDC, the
magnitude of dobutamine-induced changes in LV function
and LV geometry would predict the magnitude of sponta-
neous recovery of LV function. This prospective study was
designed to examine the prognostic value of myocardial
functional reserve as determined by dobutamine echocardi-
ography in the acute or subacute phases of IDC.
METHODS
Patient population. Twenty-six consecutive patients (20
men and 6 women) who presented with new onset (4 6 3
months) IDC were identified over a 28-month period. The
diagnosis of IDC was based on:
1) LV ejection fraction (EF) ,40%,
2) LV end systolic (ES) diameter .4.5 cm,
3) LV end diastolic (ED) diameter .5.5 cm on echocar-
diography, and
4) absence of significant coronary artery disease, primary
valvular heart disease, long-standing or uncontrolled
systemic hypertension, corpulmonale, chronic systemic
disease involving the heart muscle, drug abuse, admin-
istration of adriamycin and HIV disease.
Patients were not on inotropic support at the time of
enrollment. Of the 26 patients, four were excluded. One
had inadequate apical echocardiographic windows, one
normalized LV function between enrollment and the sched-
uled dobutamine study and two did not participate. The
mean age of the final 22 study patients (17 men, 5 women)
was 46 6 14 years (range 27 to 70 years). All patients were
in normal sinus rhythm except one who had atrial fibrilla-
tion at entry and at follow-up examination. Significant
coronary disease was excluded by stress thallium in two
patients and coronary angiography in 11 patients. Seven of
these patients had normal coronary angiograms, two had
mild to moderate (#50%) proximal left anterior descending
coronary artery stenoses, one had undergone right coronary
artery angioplasty in the remote past and had normal
coronary angiogram at the time of onset of IDC and one
was post coronary artery bypass surgery, had normal LVEF
postbypass surgery and had patent saphenous vein bypass
grafts on angiography to all three vascular territories at the
time of onset of IDC.
Cardiac medications at the time of dobutamine echocar-
diography and follow-up procedures included angiotensin-
converting enzyme (ACE) inhibitors and diuretics in all
patients, and digoxin (n 5 19), coumadin (n 5 5), aspirin
(n 5 2), amiodarone (n 5 2), beta-blockers (n 5 3) and
nitrates (n 5 4) in others. The medical management of the
patients was directed by their internist/cardiologist. Two
patients (one with and two without spontaneous improve-
ment in LVEF on follow-up) were treated with carvedilol
during follow up.
Study protocol. The study was approved by the Institu-
tional Review Board at the Cedars Sinai Medical Center
and informed patient consent was obtained. All patients
underwent an echocardiogram at baseline, during low and
peak doses of dobutamine and at follow-up. Follow up was
performed at six months and 12 months unless:
1) nonmedical intervention for poor pump function oc-
curred or
2) LVEF normalized before this period.
At follow-up visits, symptoms, medications and intervening
events such as rehospitalization, surgery and enrollment for
cardiac transplantation were recorded. Normalization of
LVEF during follow-up visits occurred in five patients (4 of
these patients had a normal LVEF by first follow-up). Left
ventricular reduction surgery was performed in three pa-
tients. One patient underwent this procedure at three
weeks, one at four months and one a year after enrollment
in this study. We excluded the patient who underwent LV
reduction surgery at three weeks after dobutamine echocar-
diography from analysis of the final LVEF. This patient had
Abbreviations and Acronyms
ACE 5 angiotensin converting enzyme
ED 5 end diastole or diastolic
EF 5 ejection fraction
ES 5 end systole or systolic
IDC 5 idiopathic dilated cardiomyopathy
LV 5 left ventricle or ventricular
NYHA 5 New York Heart Association
RV 5 right ventricle, right ventricular
WMSI 5 wall motion score index
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her LVEF increase from 25% to 35% on dobutamine
infusion.
The interval between the time of diagnosis of IDC and
dobutamine echocardiography was 4 6 3 months and
between dobutamine echocardiography and follow-up as-
sessment was 6 6 4 months.
Two-dimensional and Doppler echocardiogram. This
was performed at rest in the left lateral decubitus position
with a commercially available ultrasound system (Sequoia
256, Mountain View, California) using a variable frequency
phased array transducer (2 to 3.5 MHz) and using conven-
tional methods (30–36). Left ventricular ES and ED
dimensions and posterior wall ES and ED thickness were
obtained in the parasternal long axis views. Parasternal short
axis views were obtained at the papillary muscle level.
Global LV mass was obtained by tracing LV endocardial
and epicardial borders in ED in this view and measuring
LVED length in apical four- and two-chamber views. Left
ventricular mass (g/ml) was obtained by dividing global LV
mass by LVED volume. Left ventricular ejection fraction was
measured by the modified Simpson method (30) from apical
four- and two-chamber views. Wall motion score index
(WMSI) was measured as the sum of segmental scores (1 5
normal, 2 5 mildly hypokinetic, 2.5 5 markedly hypoki-
netic, 3 5 akinetic, 4 5 dyskinetic) divided by the number
of segments visualized (30). Left ventricular sphericity index
in ED and ES was defined as the ratio of LV length, from
apex to the middle of mitral annular plane to LV width, at
mid point of LV length in the four-chamber view. Right
ventricular (RV) fractional shortening was calculated as
percent RV shortening by measuring maximal RV width in
ES and ED in apical four-chamber view.
A low frequency (2.5 MHz) transducer was used for all
Doppler examinations. Severity of mitral and tricuspid
regurgitation was assessed visually by color flow Doppler as
mild, moderate, moderately severe or severe (31) and graded
on a scale from 11 to 41. The maximum RV-right atrial
gradient was obtained with the continuous wave Doppler
using standard method (32). Peak E, peak A and deceler-
ation time were measured by examination of the mitral
inflow velocity with the pulsed Doppler technique, and the
sample volume positioned at the tips of the mitral leaflets
(33). Isovolumetric relaxation time was measured by placing
pulsed wave sample volume in the LV outflow tract (34).
Due to the merging of E- and A-waves in six patients and
atrial fibrillation in one patient, the peak dobutamine E-
and A-waves and deceleration time could not be recorded in
seven patients. A clear Doppler tricuspid flow signal to
record pulmonary artery systolic pressure was recordable at
baseline in only nine study patients and at peak dobutamine
in three study patients.
Dobutamine echocardiography. Ten to 40 mg/kg/min of
dobutamine was infused at incremental doses of 2.5, 5, 10,
20, 30 and 40 m/kg/min at 3-min intervals through a
19-gauge cannula inserted into a forearm vein. Two-
dimensional and Doppler images were acquired after each
dose of dobutamine. No complications occurred in any
patient except one who developed ventricular couplets or
triplets with varying morphology. Dobutamine infusion was
stopped if maximum dose (40 mg/kg/min) was reached, LV
function normalized, 75% of target heart rate (220 2 age)
was achieved or complex ventricular ectopy developed.
All studies were stored on 1⁄2-inch videotape. Selected
views in baseline, peak-dobutamine and on follow-up visits
were digitized for LVEF measurement, sphericity index,
mitral inflow and LV outflow waves and for parameters
listed in Appendix 1 (35–37). An average of three measure-
ments was taken for patients in sinus rhythm and six
measurements for the patient in atrial fibrillation. We
analyzed variables at each dose of dobutamine and found
progressive improvement in LV systolic function, dimen-
sions and geometry. Data at baseline and peak dose of
dobutamine are presented. To assess the variability in
interpretation, all echocardiograms were analyzed indepen-
dently by two of the investigators (TZN, RJS). The repro-
ducibility of the measurements was calculated on the basis
of standard error of the estimate; both interobserver and
intraobserver variations were #5% for pre- and postdobu-
tamine echocardiography and follow-up LVEF.
Statistical analysis. On the basis of final follow-up LVEF,
we divided patients into two groups: group 1, follow-up
LVEF .40% and group 2, follow-up LVEF ,40%.
Change in LVEF from baseline was greater than 14% in all
patients in group 1 except one whose LVEF increased by
9% and was less than 6% in all patients in group 2 except
one in whom LVEF increased by 12%. Baseline variables
between these groups and changes in the variables from
baseline on dobutamine infusion and on follow-up in the
two groups were compared by Student unpaired t test.
Using all 21 patients, association between baseline clinical
and echocardiographic variables and final LVEF (and with
change in LVEF from baseline) was assessed with the
Pearson correlations and scatterplots. Multiple regression
was performed to predict follow-up LVEF as an outcome
variable. To assess the relative influence of significant
predictors of follow-up LVEF, several different regression
models were fit. Pearson correlation analyses was also
performed using LV sphericity in ED or ES or RV
fractional shortening as outcome variables. For these three
outcome variables only their prior baseline and dobutamine
values were used as dependent variables. Data are expressed
as mean 6 SD. A p value of ,0.05 was considered
significant.
RESULTS
Mean follow-up LVEF of patients who improved (group 1,
follow-up LVEF .40%) was 53 6 11% and of patients who
did not improve (group 2, follow-up LVEF ,40%) was
21 6 8%. Table 1 shows the clinical and echocardiographic
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parameters of the study population divided into two groups
based on the follow-up echocardiogram.
There was no significant difference in baseline demo-
graphic or echocardiographic chamber dimensions or func-
tion between the two groups. There was, however, a
significantly lower baseline LV WMSI and a greater LV
mass (g/ml) in group 1. Group 1 also had a longer
deceleration time, which correlated with baseline LV mass
(r 5 0.62, p 5 0.003).
Pulmonary artery pressure was 41 6 11 in group 1 and
35 6 7 mm Hg in group 2 (p 5 0.29).
Effect of gender. Women had a higher baseline LVEF
compared with men (31 6 6% vs. 23 6 8%, p 5 0.05).
However, there was no significant difference in LVEF at
follow-up (45 6 6% vs. 34 6 20%, p 5 0.29) or in change
in LVEF (13 6 10% vs. 10 6 19%) on follow-up in women
versus men.
Endomyocardial biopsy findings. Of the eight patients
who underwent endomyocardial biopsy, three showed fibro-
sis, three showed myocyte hypertrophy, one showed inflam-
mation and one was normal. All three patients who showed
hypertrophy improved on follow-up visits whereas all three
patients who had fibrosis on endomyocardial biopsy did not
improve on follow up.
Response to dobutamine. Table 2 shows the change in
hemodynamic and echocardiographic variables in response
to dobutamine. Despite no significant difference in changes
in heart rate or mean blood pressure at peak dobutamine
infusion, a significantly greater improvement in LV WMSI,
LVEF and LV stroke volume occurred in group 1 versus
group 2. In addition, the ES LV cavity became significantly
less spherical in group 1 versus group 2 patients. No
significant difference was observed in mitral regurgitation
(mean decrease by one grade in both groups). A direct
correlation between baseline LV mass/ml and LVEF on
dobutamine (Pearson r 5 0.65, p 5 0.001) was observed.
Direct correlations between LVEF on dobutamine and LV
sphericity in ED on dobutamine (r 5 0.54, p 5 0.01) and
LV sphericity in ES on dobutamine (r 5 0.62, p 5 0.001)
were also observed. Because of this correlation LV sphericity
in ES or ED on dobutamine was not used in the regression
model to predict follow-up LVEF.
Serial echocardiographic follow-up study. Follow-up pe-
riod for patients in group 1 was 6.5 6 4 months and for
those in group 2 was 6 6 3 months. Table 3 describes the
follow-up echocardiographic variables in the two groups.
No significant change or slight worsening between initial
and follow-up studies occurred in group 2 in WMSI, LVEF
and LV cavity dimensions in ES and ED. The LV became
more spherical and LV filling continued to have a restrictive
filling pattern. In contrast, significant improvement in LV
as well as RV systolic function, LV chamber dimensions and
LV sphericity occurred in patients in group 1. In addition,
LV filling improved from a restrictive to a nonrestrictive
pattern. No significant change in LV mass occurred in
either group, although compared with baseline, follow-up
LV mass was slightly higher in group 1. Figure 1 shows the










Age 48 6 16 45 6 12 0.57
BSA 2.03 6 0.18 2.01 6 0.18 0.78
NYHA class 2.6 6 0.8 3.1 6 0.8 0.18
Dobutamine dose
(mg/kg/min)
27 6 11 32 6 11 0.29
HR (beats/min) 85 6 17 88 6 16 0.65
BPmean (mm Hg) 89 6 13 88 6 17 0.89
LV mass (g) 247 6 59 208 6 58 0.13
LV mass (g/ml) 1.25 6 0.24 0.96 6 0.27 0.02
ESwallstress 87 6 18 98 6 27 0.29
EF (%) 27 6 8 24 6 7 0.25
WMSI 2.27 6 0.21 2.51 6 0.18 0.01
ESD (mm) 5.4 6 0.83 5.75 6 0.83 0.32
EDD (mm) 6.16 6 0.9 6.61 6 0.61 0.18
SFr (%) 26 6 6 20 6 11 0.15
EMI (cm/s) 0.79 6 0.15 0.89 6 0.22 0.26
AMI (cm/s) 0.63 6 0.25 0.46 6 0.32 0.24
E/A ratioMI 1.71 6 1.34 2.56 6 1.26 0.17
Decel TimeMI (ms) 159 6 61 96 6 42 0.01
IVRT 82 6 22 99 6 37 0.29
Sphericity indexED 1.63 6 0.14 1.63 6 0.25 0.95
Sphericity indexES 1.81 6 0.22 1.81 6 0.32 0.97
Mitral regurgitation grade 1.9 6 1.26 2.85 6 0.9 0.07
Values are mean 6 SD.
BP 5 blood pressure; BSA 5 body surface area; EDD 5 end diastolic diameter;
EF 5 ejection fraction; ES 5 end systolic; ESD 5 end systolic diameter; FU 5
follow up; HR 5 heart rate; IVRT 5 isovolumetric relaxation time; MI 5 mitral in
flow Doppler; NYHA 5 New York Heart Association; SFr 5 right ventricular
fractional shortening; WMSI 5 wall motion score index.
Table 2. Change in Hemodynamic and Echocardiographic








Heart rate* 34 6 17 35 6 11 0.93
Blood pressure
(mean)*
23 6 13 20.6 6 17 0.74
Ejection fraction* 27 6 14 10.5 6 5 0.001
Sphericity indexED* 0.35 6 0.34 0.14 6 0.23 0.09
Sphericity indexES* 0.60 6 0.43 0.13 6 0.21 0.003
Wall motion score
index*
20.69 6 0.29 20.37 6 0.30 0.02
Stroke volume* 34 6 27 6 6 17 0.012
ESwallstress* 243 6 16 263 6 26 0.34
Fractional shortening
RV*
16 6 14 11 6 12 0.31
Values are mean 6 SD.
* 5 change; ED 5 end-diastole; ES 5 end-systole; FU 5 follow up; RV 5 right
ventricle.
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changes in echocardiographic variables from baseline to
follow-up in the two groups. Left ventricular ejection
fraction increased by 26 6 12% in group 1 and decreased by
3 6 8% in group 2 (p , 0.001). Left ventricular ED
dimension decreased in group 1 and increased in group 2
(delta 5 20.35 6 0.88 cm vs. 0.25 6 0.67 cm, p 5 0.09).
A decrease in LV dimensions in group 1 was associated with
a decrease in ES wall stress, whereas an increase in LV
dimensions in group 2 was associated with an increase in ES
wall stress (delta 5 228 6 21 vs. 42 6 99 G/cm2, p 5
0.043). In addition, LV filling became less restrictive, with
a greater decrease in mitral in flow E/A ratio in group 1
versus group 2 (delta 5 20.70 6 1.28 vs. 20.41 6 1.36,
p 5 NS) and a greater increase in deceleration time in group
1 versus group 2 (delta 5 36 6 72 ms vs. 21 6 50 ms, p 5
0.24).
Figure 2 shows the LVEF at baseline, peak dobutamine
and follow up in the two groups. Correlation between
dobutamine LVEF and follow-up LVEF was 0.84, between
DEF on dobutamine (dobutamine EF–baseline LVEF) and
follow-up LVEF was 0.71 and between DLVEF on dobut-
amine and DLVEF on follow-up (follow-up LVEF–
baseline LVEF) was 0.81. Table 4 shows the correlation
between baseline clinical and echocardiographic variables as
well as contractile reserve of the LV, measured as an
increase in LVEF on dobutamine, to LVEF on follow up.
Because higher correlations of baseline clinical, echocardio-
graphic and dobutamine echocardiographic variables were
found for final LVEF than they were for change in LVEF
from baseline, correlations with final LVEF are shown. The
baseline variables that were significantly predictive of
follow-up LVEF (or change in LVEF on follow-up) were
DT with a correlation of 0.69 (and 0.57), WMSI with a
correlation of 20.63 (and 20.38), LV mass (g/ml) with a
correlation of 0.56 (and 0.48) and LVEF on dobutamine
with a correlation of 0.84 (and 0.69) for follow-up LVEF
(or change in LVEF from baseline, respectively). Figure 3
shows the correlation between LVEF on dobutamine and at
follow-up. Using any of baseline variables DT, WMSI or
LV mass to predict follow-up LVEF gave adjusted
R-square of 0.47, 0.39 and 0.31, respectively. Left ventric-
ular ejection fraction on dobutamine (or DLVEF 5 dobut-
amine, LVEF–baseline LVEF) added significantly to pre-
dictive power, r2 5 0.74, 0.73 and 0.70 with DT, WMSI
and LV mass, respectively. However if LVEF on dobut-
amine (or DLVEF 5 dobutamine LVEF–baseline LVEF)
was entered first, none of the other three variables added
significantly to prediction. Baseline LV sphericity in ED
Figure 1. Changes in LV WMSI, ESD, mitral inflow E-wave, LV
mass (g/ml) and SIED in patients whose follow-up LVEF was
.40% (group 1, solid black bars) versus patients whose follow-up
LVEF was ,40% (group 2, white bars) are shown. * 5 p , 0.05
versus group 1. EF 5 ejection fraction; ESD 5 end-systolic
diameter; LV 5 left ventricular; SIED 5 end-diastolic sphericity
index; WMSI 5 wall motion score index.
Figure 2. Left ventricular ejection fraction at baseline, in response
to dobutamine and on follow-up in patients with LVEF .40%
(left panel) and with LVEF ,40% (right panel) on follow-up.
Horizontal bars indicate the mean value of LVEF in each group.
LVEF 5 left ventricular ejection fraction.









NYHA class 1.2 6 0.4 2.25 6 1 0.008
LV mass (g) 202 6 42 209 6 32 0.67
LV mass (g/ml) 1.38 6 0.27 0.99 6 0.32 0.007
ESwallstress 59 6 15 139 6 102 0.026
EF (%) 21 6 8 53 6 11 , 0.001
WMSI 2.33 6 0.26 1.40 6 0.43 , 0.001
ESD (mm) 4.54 6 0.56 5.95 6 0.91 , 0.001
EDD (mm) 5.82 6 0.52 6.82 6 0.94 0.008
SFr (%) 34 6 11 22 6 16 0.068
EMI (cm/s) 0.63 6 0.17 0.95 6 0.24 0.006
AMI (cm/s) 0.78 6 0.24 0.62 6 0.39 0.34
E/A ratioMI 1.14 6 1.38 1.94 6 1 0.04
Decel time (ms) 195 6 58 103 6 25 , 0.001
IVRT 93 6 46 91 6 18 0.93
Sphericity indexED 2.02 6 0.33 1.51 6 0.22 , 0.001
Sphericity indexES 2.41 6 0.44 1.64 6 0.21 , 0.001
Mitral regurgitation
grade
0.8 6 0.89 2.06 6 1.01 0.01
Values are mean 6 SD.
EDD 5 end-diastolic diameter; EF 5 ejection fraction; ES 5 end systolic;
ESD 5 end-systolic diameter; FU 5 follow-up; IVRT 5 isovolumetric relaxation
time; LV 5 left ventricular; MI 5 mitral in flow Doppler; NYHA 5 New York
Heart Association; SFr 5 right ventricular fractional shortening; WMSI 5 wall
motion score index.
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(r 5 0.13, p 5 0.6) or ES (r 5 0.26, p 5 0.25) did not
significantly correlate with the follow-up LV sphericity in
ED or ES, but LV sphericity on dobutamine in ED (r 5
0.70, p 5 0.0004) and ES (r 5 0.69, p 5 0.0005) did
correlate with the follow-up LV sphericity. The baseline RV
fractional shortening correlated with the follow-up RV
fractional shortening (r 5 0.49, p 5 0.02), whereas frac-
tional shortening on dobutamine did not (r 5 0.37, p 5
0.09) correlate with follow-up RV fractional shortening.
Status at follow-up. No cardiac events occurred in any of
the 10 patients with follow-up LVEF .40%. Six patients
were in New York Heart Association (NYHA) class I, of
these five had complete normalization of LVEF and four
were in NYHA class II. Five of the 11 patients with
follow-up LVEF ,40% had events. Two patients had
recurrent admissions for congestive heart failure, another
one was admitted with congestive heart failure and ventric-
ular tachycardia, one with hypotension and congestive heart
failure, and one was listed for heart transplantation. Of
these, two patients underwent LV reduction surgery. Of the
remaining six patients, two remained in NYHA class II, two
improved from class III to class II and two improved from
class III to class I.
DISCUSSION
The major finding of this study is that early after the
diagnosis of IDC, the LV contractile response and change
in LV geometry in response to dobutamine predicted late
recovery of LV function. Both the response to dobutamine
infusion and the late clinical and hemodynamic improve-
ment were directly related to baseline LV mass per unit
volume. Other echocardiographic parameters did not pre-
dict future cardiac function.
Prognostic value of contractile reserve. Our findings
extend the results of earlier studies (27,28) that demon-
strated the prognostic value of contractile reserve in IDC.
These prior studies were performed in patients with long-
standing dilated cardiomyopathy, whereas we limited our
assessment to patients with recent onset dilated cardiomy-
opathy and we also assessed LV mass and LV geometry and
RV function. Our study also extends a previously estab-
lished correlation between LV hypertrophy and contractile
reserve (38), to demonstrate that there is a further correla-
tion between LV mass, response to inotropic stimulation
and spontaneous late recovery of LV function.
The potential for substantial, and even complete, recovery
of cardiac function in patients with acute and subacute IDC
has been established by several investigators (4–6). Similar
to the findings of previous reports (9,10), we found a
restricted mitral inflow pattern to be associated with poor
LVEF on follow-up. Furthermore, improvement in systolic
function was associated with resolution of the restrictive LV
filling (14), a less spherical LV geometry and decrease in
wall stress.
Prognostic value of LV mass. In addition, we found
preservation of LV mass to be associated with an improve-
ment in LV function. The presence of LV hypertrophy in
IDC has been associated with a good prognosis in previous
studies (25,26,38). Pelliccia et al. (26) showed in 30 IDC
patients that the ratio of myofibrillar volume to total cell
volume was significantly lower in patients who had poor
Figure 3. Linear regression analysis showing correlation between
LVEF on dobutamine and LVEF on follow-up. LVEF 5 left
ventricular ejection fraction. y 5 10.8108 1 1.08*x; adjusted r2 5
0.68.








ESD (mm) 20.21 0.34
EDD (mm) 0.22 0.34
Ejection fraction (%) 0.37 0.09
Fractional shortening RV (%) 0.38 0.08
EMI (cm/s) 20.07 0.75
AMI (cm/s) 0.42 0.079
E/A ratioMI 20.33 0.18
Deceleration time (ms) 0.69 0.0006
IVRT (ms) 20.43 0.065
Sphericity index (ED) 0.12 0.61
Sphericity index (ES) 0.34 0.13
Mitral regurgitation 20.20 0.41
End systolic wall stress (g/cm2) 20.31 0.17
LV mass 0.26 0.25
LV mass/ml 0.56 0.008
Dobutamine
LV ejection fraction 0.84 0.0006
Sphericity indexED 0.64 0.0017
Sphericity indexES 0.71 0.0004
n 5 21. Patient who underwent LV reduction surgery at three weeks after dobutamine
echocardiography was excluded from analysis.
EDD 5 end-diastolic diameter; ESD 5 end-systolic diameter; IVRT 5 isovolu-
metric relaxation time; LV 5 left ventricle; MI 5 mitral in flow Doppler; RV 5 right
ventricle; WMSI 5 wall motion score index.
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prognosis at one year than those who recovered. Similarly,
others have reported that low myofibril volume (39) and
electron microscopic evidence of myofilament loss indicate a
poor prognosis in patients with IDC (40). Restoration of
LV mass by recombinant growth hormone therapy also
improves cardiac hemodynamics and clinical function in
patients with ischemic cardiomyopathy (41). Our study
findings suggest that the presence of LV hypertrophy
implies the presence of myocardial contractile reserve, which
in turn predicts recovery of LV function.
Myocardial response to dobutamine. The mechanism by
which greater baseline LV mass relates to subsequent
recovery of function is not clear. The dobutamine dose,
change in heart rate, mean blood pressure, reduction in
mitral regurgitation and the decline in ES wall stress in
response to dobutamine was similar in both groups. Thus
the factor differentiating the patients who recovered LV
function from those who did not was principally the
myocardial inotropic response. The LV mass in IDC may
determine the contractile response to dobutamine and
reflects both beta receptor number and integrity and the
potential for recovery of LV function. This capacity for
recovery may be independent of subsequent pharmacologic
therapy with ACE inhibitor and beta blocker therapy
because the treatment pattern in both groups was similar
and most of our patients were on ACE inhibitor therapy.
In our study, baseline RV function and improvement in
response to dobutamine was not significantly different in
both groups of patients, but improvement in LVEF was
associated with a concurrent improvement in RV function.
These differences in the RV versus LV responsiveness may
represent the limitations of echocardiography for the assess-
ment of RV function or relate to the smaller myocardial
mass of RV wall and its lower beta receptor density.
Study limitations. Because patients may have asymptom-
atic LV dysfunction for varying time intervals before their
diagnosis, our study findings may be considered to be more
relevant to “newly diagnosed” rather than “new onset” IDC.
Although our findings establish a correlation between con-
tractile reserve with LV mass, our proposed mechanism
involving beta-receptor density is speculative, because we
did not measure beta-receptor density, adenylcyclase activity
or G protein activity. The failure of contractile reserve with
dobutamine does not preclude recovery from heart failure,
because four patients in group 2 improved functional class
despite poor LVEF. Other echocardiographic methodologic
limitations include:
1) potential imprecision in the measurement of RV func-
tion by echocardiography, which may have accounted for
the weak predictive value of RV contractile reserve in our
study, and
2) the limited ability to record discrete pressure gradients
between right atrium and RV and between left atrium
and LV at peak dobutamine infusion due to a reduction
in the tricuspid and mitral regurgitation envelopes.
Although we measured LV mass per unit ml at the time of
baseline echocardiography, the correlation of LV mass with
dobutamine response and with follow-up LVEF is a post-
hoc analysis and not based on a priori hypothesis.
As with many cases of dilated cardiomyopathy, the
etiology is unknown in our patients. Thus, the recovery
process and time is likely to be different based on underlying
etiology. Finally, because the sample size is small and the
follow-up period is relatively short, our findings need to be
confirmed in a larger cohort of patients.
Implications. Our findings confirm the limited prognostic
value of clinical and conventional echocardiographic param-
eters in patients with new onset IDC. Conversely, this is the
first study to demonstrate that contractile reserve on dobut-
amine echocardiography has important prognostic value in
patients with newly diagnosed IDC. The data suggest that
dobutamine echocardiography is a useful test in the assess-
ment of patients with recently diagnosed IDC and may also
be useful as part of pretransplant evaluation in patients with
IDC. Conservative management without potentially unnec-
essary transplantation might be considered in patients who
show improvement in LV contractility and geometry in
response to dobutamine. The absence of a significant
response to dobutamine may imply a poor chance of
recovery, suggesting a greater role for transplantation or LV
reduction surgery. This approach to management could help
triage patients with new onset IDC.
APPENDIX
APPENDIX 1: ECHOCARDIOGRAPHIC MEASUREMENTS
LV mass (g) (35): V 5 5/6A 3 L, L 5 LV length from
base to LV apex. LVM 5 [Vt (ep) 2 Vc (en)] 3 1.05, Vt 5
total LV volume, Vc 5 chamber volume, midparasternal
short axis view. 1.05 5 specific gravity of the cardiac muscle.
Left ventricular end-systolic meridianal wall stress
(g/cm2)36: ESWALL STRESS 5 [(1.35) (MBP) (LVES)]/[(4)
(LVPWES) (1 1 LVPWES/LVES)], MBP 5 (2DBP 1
SBP)/3, DBP 5 diastolic blood pressure and SBP 5
systolic blood pressure. 1.35 is the factor to convert pressure
from mm Hg to g/cm2.
Right ventricular shortening fraction (FSRV) (37) 5 100%
3 (RVED – RVES)/RVED.
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